A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19464 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Fei-Fei Tang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Etoposide, Induction Chemotherapy, Leukemia, Promyelocytic, Acute. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Peking University People's Hospital Research and Development Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
There is an urgent need for an oral, efficient and safe regimen for high‐risk APL under the pandemic of COVID‐19. We retrospectively analysed 60 high‐risk APL patients. For induction therapy (IT), in addition to all‐trans retinoic acid (ATRA) and oral arsenic (RIF), 22 patients received oral etoposide (VP16) as cytotoxic chemotherapy (CC), and 38 patients received intravenous CC as historical control group. The median dose of oral VP16 was 1000 mg [interquartile rage (IQR), 650–1250]. One patient died during IT in the control group, 59 evaluable patients (100%) achieved complete haematological remission (CHR) after IT and complete molecular remission (CMR) after consolidation therapy. The median time to CHR and CMR was 36 days (33.8–44) versus 35 days (32–42; p = 0.75) and 3 months (0.8–3.5) versus 3.3 months (2.4–3.7; p = 0.58) in the oral VP16 group and in the control group. Two (9.1%) and 3 (7.9%) patients experienced molecular relapse in different group respectively. The 2‐year estimated overall survival and event‐free survival were 100% versus 94.7% ( p = 0.37) and 90.9% versus 89.5% ( p = 0.97) respectively. A completely oral, efficient and safe induction regimen including oral VP16 as cytoreductive chemotherapy combined with ATRA and RIF is more convenient to administer for patients with high‐risk APL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking Univer…
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
ORCID-Profile: Fei-Fei Tang, Wen-Bing Duan, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Qian Jiang, Hao Jiang
Förderung
- National Key Research and Development Program of China
- Peking University People's Hospital Research and Development Foundation
Zitieren
APA
Tang, F. F., Duan, W. B., Liu, X. H., Lu, S. Y., Zhao, X. S., Qin, Y. Z., Jia, J. S., Wang, J., Gong, L. Z., Jiang, Q., Zhao, T., Shi, H. X., Chang, Y. J., Huang, X. J., & Jiang, H. (2024). A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy. British Journal of Haematology. https://doi.org/10.1111/bjh.19464
Vancouver
Tang FF, Duan WB, Liu XH, Lu SY, Zhao XS, Qin YZ, et al. A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy. British Journal of Haematology. 2024. doi:10.1111/bjh.19464
BibTeX
@article{Tang2024,
author = {Tang, Fei-Fei and Duan, Wen-Bing and Liu, Xiao-Hong and Lu, Sheng-Ye and Zhao, Xiao-Su and Qin, Ya-Zhen and Jia, Jin-Song and Wang, Jing and Gong, Li-Zhong and Jiang, Qian and Zhao, Ting and Shi, Hong-Xia and Chang, Ying-Jun and Huang, Xiao-Jun and Jiang, Hao},
title = {A complete oral regimen for induction therapy of patients with high‐risk APL : An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19464}
}
EUVIMED